

Literatura

1. Perz JF, Armstrong GL, Farrington LA et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *J Hepatol* 2006; 45(4): 529–538. doi: 10.1016/j.jhep.2006.05.013.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology* 2007; 132(7): 2557–2576. doi: 10.1053/j.gastro.2007.04.061.
3. Law MG, Roberts SK, Dore GJ et al. Primary hepatocellular carcinoma in Australia, 1978–1997: increasing incidence and mortality. *Med J Aust* 2000; 173(8): 403–405. doi: 10.5694/j.1326-5377.2000.tb139267.x.
4. Benhamiche AM, Faivre C, Minello A et al. Time trends and age-period-cohort effects on the incidence of primary liver cancer in a well-defined French population: 1976–1995. *J Hepatol* 1998; 29(5): 802–806. doi: 10.1016/s0168-8278(98)80262-6.
5. Cancer today. [online]. Available from: <https://gco.iarc.fr/today/home>.
6. Jemal A, Bray F, Center MM et al. Global cancer statistics. *CA Cancer J Clin* 2011; 61(2): 69–90. doi: 10.3322/caac.20107.
7. SVOD. Epidemiologie zhoubných nádorů v České republice. [online]. Dostupné z: <https://www.svod.cz/>.
8. Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2021; 71(3): 209–249. doi: 10.3322/caac.21660.
9. Llovet JM, Bustamante J, Castells A et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. *Hepatology* 1999; 29(1): 62–67. doi: 10.1002/hep.510290145.
10. Lee D, Choi SW, Kim M et al. Discovery of differentially expressed genes related to histological subtype of hepatocellular carcinoma. *Biotechnol Prog* 2003; 19(3): 1011–1015. doi: 10.1021/bp025746a.
11. Rivenbark AG, Coleman WB. The use of epigenetic biomarkers for preclinical detection of hepatocellular carcinoma: potential for noninvasive screening of high-risk populations. *Clin Cancer Res* 2007; 13(8): 2309–2312. doi: 10.1158/1078-0432.CCR-07-0086.
12. Wang XW, Hussain SP, Huo TI et al. Molecular pathogenesis of human hepatocellular carcinoma. *Toxicology* 2002; 181–182: 43–47. doi: 10.1016/s0300-483x(02)00253-6.
13. Nakanuma Y, Terada T, Ueda K et al. Adenomatous hyperplasia of the liver as a precancerous lesion. *Liver* 1993; 13(1): 1–9. doi: 10.1111/j.1600-0676.1993.tb00597.x.
14. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. *Lancet* 2003; 362(9399): 1907–1917. doi: 10.1016/S0140-6736(03)14964-1.
15. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. *CA Cancer J Clin* 2005; 55(2): 74–108. doi: 10.3322/canjclin.55.2.74.
16. Vescovo T, Refolo G, Vitagliano G et al. Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma. *Clin Microbiol Infect* 2016; 22(10): 853–861. doi: 10.1016/j.cmi.2016.07.019.
17. Tarocchi M, Polvani S, Marroncini G et al. Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. *World J Gastroenterol* 2014; 20(33): 11630–11640. doi: 10.3748/wjg.v20.i33.11630.
18. Wang B, Majumder S, Nuovo G et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. *Hepatology* 2009; 50(4): 1152–1161. doi: 10.1002/hep.23100.
19. Majumder M, Ghosh AK, Steele R et al. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. *J Virol* 2001; 75(3): 1401–1407. doi: 10.1128/JVI.75.3.1401-1407.2001.

20. Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. *J Carcinog* 2017; 16: 1. doi: 10.4103/jcar.JCar_9_16.
21. Thorgeirsson SS, Lee JS, Grisham JW. Functional genomics of hepatocellular carcinoma. *Hepatology* 2006; 43(2 Suppl 1): S145–E150. doi: 10.1002/hep.21063.
22. Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. *N Engl J Med* 1997; 336(26): 1855–1859. doi: 10.1056/NEJM199706263362602.
23. Sung JJ, Tsoi KK, Wong VW et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. *Aliment Pharmacol Ther* 2008; 28(9): 1067–1077. doi: 10.1111/j.1365-2036.2008.03816.x.
24. Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. *Dig Dis* 2016; 34(4): 382–386. doi: 10.1159/000444551.
25. Fattovich G, Stroffolini T, Zagni I et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. *Gastroenterology* 2004; 127(5 Suppl 1): S35–50. doi: 10.1053/j.gastro.2004.09.014.
26. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. *Hepatology* 2011; 53(3): 1020–1022. doi: 10.1002/hep.24199.
27. Vauthey JN, Lauwers GY, Esnaola NF et al. Simplified staging for hepatocellular carcinoma. *J Clin Oncol* 2002; 20(6): 1527–1536. doi: 10.1200/JCO.2002.20.6.1527.
28. Okuda K, Ohtsuki T, Obata H et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. *Cancer* 1985; 56(4): 918–928. doi: 10.1002/1097-0142(19850815)56:4<918::aid-cnrcr2820560437>3.0.co;2-e.
29. Kudo M, Kitano M, Sakurai T et al. General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: the outstanding achievements of the liver cancer study group of Japan. *Dig Dis* 2015; 33(6): 765–770. doi: 10.1159/000439101.
30. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. *Hepatology* 2000; 31(4): 840–845. doi: 10.1053/he.2000.5628.
31. Leung TW, Tang AM, Zee B et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. *Cancer* 2002; 94(6): 1760–1769. doi: 10.1002/cncr.10384.
32. Chevret S, Trinchet JC, Mathieu D et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. *J Hepatol* 1999; 31(1): 133–141. doi: 10.1016/s0168-8278(99)80173-1.
33. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. *Semin Liver Dis* 1999; 19(3): 329–338. doi: 10.1055/s-2007-1007122.
34. Vogel A, Cervantes A, Chau I et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2018; 29(Suppl 4): iv238–iv255. doi: 10.1093/annonc/mdy308.
35. Urbánek P, Hříbek P. Hepatocelulární karcinom z pohledu gastroenterologa/hepatologa. *Klin Onkol* 2020; 33(Suppl 3): 34–44. doi: 10.14735/amko20203S34.
36. Třeška V. Chirurgická léčba hepatocelulárního karcinomu. *Klin Onkol* 2020; 33(Suppl 3): 30–33. doi: 10.14735/amko20203S30.
37. Tokarčík J, Slížová D, Andrašina I et al. Systemic treatment for hepatocellular carcinoma. *Klin Onkol* 2020; 33(5): 356–361. doi: 10.14735/amko2020356.

38. National Comprehensive Cancer Network. Guidelines. [online]. Available from: <https://www.nccn.org/>.
39. ESMO guidelines. [online]. Available from: <https://www.esmo.org/guidelines>.
40. Modrá kniha České onkologické společnosti. [online]. Dostupné z: <https://www.linkos.cz/lekar-a-multidisciplinari-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/>.
41. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996; 334(11): 693–699. doi: 10.1056/NEJM199603143341104.
42. Mazzaferro V, Llovet JM, Miceli R et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. *Lancet Oncol* 2009; 10(1): 35–43. doi: 10.1016/S1470-2045(08)70284-5
43. Decaens T, Roudot-Thoraval F, Hadni-Bresson S et al. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. *Liver Transpl* 2006; 12(12): 1761–1769. doi: 10.1002/lt.20884.
44. Mazzaferro V, Bhoori S, Sposito C et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. *Liver Transpl* 2011; 17(Suppl 2): S44–57. doi: 10.1002/lt.22365.
45. Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. *Hepatology* 2001; 33(6): 1394–1403. doi: 10.1053/jhep.2001.24563.
46. Liver Transplantation for hepatocellular carcinoma. The metroticket project. [online]. Available from: <http://www.hcc-olt-metroticket.org/>
47. Marsh JW, Finkelstein SD, Demetris AJ et al. Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. *Liver Transpl* 2003; 9(7): 664–671. doi: 10.1053/jlts.2003.50144.
48. Merani S, Majno P, Kneteman NM et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. *J Hepatol* 2011; 55(4): 814–819. doi: 10.1016/j.jhep.2010.12.040.
49. Toso C, Asthana S, Bigam DL et al. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. *Hepatology* 2009; 49(3): 832–838. doi: 10.1002/hep.22693.
50. Citores MJ, Lucena JL, de la Fuente S et al. Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation. *World J Hepatol* 2019; 11(1): 50–64. doi: 10.4254/wjh.v11.i1.50.
51. Abreu P, Gorgen A, Oldani G et al. Recent advances in liver transplantation for cancer: the future of transplant oncology. *JHEP Rep* 2019; 1(5): 377–391. doi: 10.1016/j.jhepr.2019.07.004.
52. Zhou L, Xu Y, Guo Z et al. Perioperative circulating tumor DNA analysis to predict patient prognosis in liver cancer. *J Clin Oncol* 2020; 38(15 suppl): 4593–4593. doi: 10.1200/JCO.2020.38.15_suppl.4593.
53. Ravaioli M, Grazi GL, Pisciglia F et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside of the Milan selection criteria. *Am J Transplant* 2008; 8(12): 254–757. doi: 10.1111/j.1600-6143.2008.02409.x.
54. Sapisochin G, Goldaracena N, Laurence JM et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study. *Hepatology* 2016; 64(6): 2077–2088. doi: 10.1002/hep.28643.
55. Sun DW, An L, Wei F et al. Prognostic significance of parameters from pretreatment (18)F-FDG PET in hepatocellular carcinoma: a meta-analysis. *Abdom Radiol (NY)* 2016; 41(1): 33–41. doi: 10.1007/s00261-015-0603-9.

56. Pomfret EA, Washburn K, Wald C et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. *Liver Transpl* 2010; 16(3): 262–278. doi: 10.1002/lt.21999.
57. Bhoori S, Sposito C, Germini A et al. The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis. *Transpl Int* 2010; 23(7): 712–722. doi: 10.1111/j.1432-2277.2010.01111.x.
58. Vitale A, Volk ML, Pastorelli D et al. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. *Hepatology* 2010; 51(1): 165–173. doi: 10.1002/hep.23260.
59. Oliverius M, Studeník P. Transplantace jater pro hepatocelulární karcinom. *Folia Gastroenterol Hepatol* 2005; 3(Suppl 1): 69–77.
60. Belghiti J, Fuks D. Liver resection and transplantation in hepatocellular carcinoma. *Liver Cancer* 2012; 1(2): 71–82. doi: 10.1159/000342403.
61. Cherqui D, Laurent A, Mocellin N et al. Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. *Ann Surg* 2009; 250(5): 738–746. doi: 10.1097/SLA.0b013e3181bd582b.
62. Wang HL, Mo DC, Zhong JH et al. Systematic review of treatment strategy for recurrent hepatocellular carcinoma: salvage liver transplantation or curative locoregional therapy. *Medicine (Baltimore)* 2019; 98(8): e14498. doi: 10.1097/MD.00000000000014498.
63. Miyagawa S, Makuuchi M, Kawasaki S et al. Criteria for safe hepatic resection. *Am J Surg* 1995; 169(6): 589–594. doi: 10.1016/s0002-9610(99)80227-x.
64. Válek V, Kala Z, Kiss I et al. Maligní ložiskové procesy jater. Diagnostika a léčba včetně minimálně invazivních metod. Praha: Grada Publishing 2006.
65. Marelli L, Stigliano R, Triantos C et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. *Cardiovasc Intervent Radiol* 2007; 30(1): 6–25. doi: 10.1007/s00270-006-0062-3.
66. Meyers MA. Neoplasms of the digestive tract: imaging, staging, and management. Philadelphia: Lippincot Raven 1998.
67. Dodd GD 3rd, Soulen MC, Kane RA et al. Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. *Radiographics* 2000; 20(1): 9–27. doi: 10.1148/radiographics.20.1.g00ja019.
68. Dawson SL, Lee MJ, Mueller PR. Nonsurgical treatment of liver tumors: seminars in interventional radiology. *Radiology* 1993; 10: 2.
69. Kemeny N, Huang Y, Cohen AM et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. *N Engl J Med* 1999; 341(27): 2039–2048. doi: 10.1056/NEJM199912303412702.
70. Sho T, Suda G, Ogawa K et al. Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting. *JGH Open* 2020; 4(1): 54–60. doi: 10.1002/jgh3.12209.
71. Yang Yi, Si T. Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis. *Cancer Biol Med* 2018; 15(3): 299–310. doi: 10.20892/j.issn.2095-3941.2017.0177.
72. Lencioni RA, Allgaier HP, Cioni D et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. *Radiology* 2003; 228(1): 235–240. doi: 10.1148/radiol.2281020718.
73. Salmi A, Turrini R, Lanzani G et al. Efficacy of radiofrequency ablation of hepatocellular carcinoma associated with chronic liver disease without cirrhosis. *Int J Med Sci* 2008; 5(6): 327–332. doi: 10.7150/ijms.5.327.

74. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. *Cancer Res* 2004; 64(19): 7099–7109. doi: 10.1158/0008-5472.CAN-04-1443.
75. Abou-Alfa GK, Johnson P, Knox JJ et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. *JAMA* 2010; 304(19): 2154–2160. doi: 10.1001/jama.2010.1672.
76. Hu B, Yang XB, Sang XT. Liver graft rejection following immune checkpoint inhibitors treatment: a review. *Med Oncol* 2019; 36(11): 94. doi: 10.1007/s12032-019-1316-7.
77. Choi BO, Jang HS, Kang KM et al. Fractionated stereotactic radiotherapy in patients with primary hepatocellular carcinoma. *Jpn J Clin Oncol* 2006; 36(3): 154–158. doi: 10.1093/jjco/hyi236.
78. Cárdenes HR, Price TR, Perkins SM et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. *Clin Transl Oncol* 2010; 12(3): 218–225. doi: 10.1007/s12094-010-0492-x.
79. Chen H, Shen ZY, Xu W et al. Expression of P450 and nuclear receptors in normal and end-stage Chinese livers. *World J Gastroenterol* 2014; 20(26): 8681–8690. doi: 10.3748/wjg.v20.i26.8681
80. Nekvindova J, Mrkvicova A, Zubanova V et al. Hepatocellular carcinoma: gene expression profiling and regulation of xenobiotic-metabolizing cytochromes P450. *Biochem Pharmacol* 2020; 177: 113912. doi: 10.1016/j.bcp.2020.113912.
81. Zhu AX, Kang YK, Yen CJ et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2019; 20(2): 282–296. doi: 10.1016/S1470-2045(18)30937-9.
82. Flem-Karlsen K, Nyakas M, Farstad IN et al. Soluble AXL as a marker of disease progression and survival in melanoma. *PLoS One* 2020; 15(1): e0227187. doi: 10.1371/journal.pone.0227187.
83. Reichl P, Fang M, Starlinger P et al. Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma. *Int J Cancer* 2015; 137(2): 385–394. doi: 10.1002/ijc.29394.
84. Brychtova V, Zampachova V, Hrstka R et al. Differential expression of anterior gradient protein 3 in intrahepatic cholangiocarcinoma and hepatocellular carcinoma. *Exp Mol Pathol* 2014; 96(3): 375–381. doi: 10.1016/j.yexmp.2014.04.002.
85. Cohen JD, Javed AA, Thoburn C et al. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. *Proc Natl Acad Sci U S A* 2017; 114(38): 10202–10207. doi: 10.1073/pnas.1704961114.
86. Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease – latest advances and implications for cure. *Nat Rev Clin Oncol* 2019; 16(7): 409–424. doi: 10.1038/s41571-019-0187-3.
87. Ko J, Baldassano SN, Loh PL et al. Machine learning to detect signatures of disease in liquid biopsies – a user's guide. *Lab Chip* 2018; 18(3): 395–405. doi: 10.1039/c7lc00955k.
88. Leung F, Kulasingam V, Diamandis EP et al. Circulating tumor DNA as a cancer biomarker: fact or fiction? *Clin Chem* 2016; 62(8): 1054–1060. doi: 10.1373/clinchem.2016.260331.
89. Jiang P, Lo YMD. The long and short of circulating cell-free DNA and the ins and outs of molecular diagnostics. *Trends Genet* 2016; 32(6): 360–371. doi: 10.1016/j.tig.2016.03.009.
90. Mattox AK, Bettgowda C, Zhou S et al. Applications of liquid biopsies for cancer. *Sci Transl Med* 2019; 11(507): eaay1984. doi: 10.1126/scitranslmed.aay1984.

91. Neumann MHD, Bender S, Krahn T et al. ctDNA and CTCs in liquid biopsy – current status and where we need to progress. *Comput Struct Biotechnol J* 2018; 16: 190–195. doi: 10.1016/j.csbj.2018.05.002.
92. Bettgowda C, Sausen M, Leary RJ et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med* 2014; 6(224): 224ra24. doi: 10.1126/scitranslmed.3007094.
93. Rossi G, Ignatiadis M. Promises and pitfalls of using liquid biopsy for precision medicine. *Cancer Res* 2019; 79(11): 2798–2804. doi: 10.1158/0008-5472.CAN-18-3402.
94. Okajima W, Komatsu S, Ichikawa D et al. Liquid biopsy in patients with hepatocellular carcinoma: circulating tumor cells and cell-free nucleic acids. *World J Gastroenterol* 2017; 23(31): 5650–5668. doi: 10.3748/wjg.v23.i31.5650.
95. Li J, Shi L, Zhang X et al. pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma. *Oncotarget* 2016; 7(3): 2646–2659. doi: 10.18632/oncotarget.6104.
96. Krebs MG, Metcalf RL, Carter L et al. Molecular analysis of circulating tumour cells—biology and biomarkers. *Nat Rev Clin Oncol* 2014; 11(3): 129–144. doi: 10.1038/nrcclinonc.2013.253.
97. Yeo W, Wong N, Wong WL et al. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. *Liver Int* 2005; 25(2): 266–272. doi: 10.1111/j.1478-3231.2005.01084.x.
98. Zhang YJ, Wu HC, Shen J et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. *Clin Cancer Res* 2007; 13(8): 2378–2384. doi: 10.1158/1078-0432.CCR-06-1900.
99. Wu HC, Yang HI, Wang Q et al. Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population. *Carcinogenesis* 2017; 38(10): 1021–1028. doi: 10.1093/carcin/bgx078.
100. Wang J, Yang L, Diao Y et al. Circulating tumour DNA methylation in hepatocellular carcinoma diagnosis using digital droplet PCR. *J Int Med Res* 2021; 49(3): 300060521992962. doi: 10.1177/0300060521992962.
101. Ren N, Ye QH, Qin LX et al. Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients. *World J Gastroenterol* 2006; 12(24): 3911–3914. doi: 10.3748/wjg.v12.i24.3911.
102. Tran NH, Kisiel J, Roberts LR. Using cell-free DNA for HCC surveillance and prognosis. *JHEP Rep* 2021; 3(4): 100304. doi: 10.1016/j.jhepr.2021.100304.
103. Ono A, Fujimoto A, Yamamoto Y et al. Circulating tumor DNA analysis for liver cancers and its usefulness as a liquid biopsy. *Cell Mol Gastroenterol Hepatol* 2015; 1(5): 516–534. doi: 10.1016/j.jcmgh.2015.06.009.
104. Liao W, Yang H, Xu H et al. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing. *Oncotarget* 2016; 7(26): 40481–40490. doi: 10.18632/oncotarget.9629.
105. Cai ZX, Chen G, Zeng YY et al. Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma. *Int J Cancer* 2017; 141(5): 977–985. doi: 10.1002/ijc.30798.
106. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. *N Engl J Med* 2004; 351(8): 781–791. doi: 10.1056/NEJMoa040766.
107. de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. *Clin Cancer Res* 2008; 14(19): 6302–6309. doi: 10.1158/1078-0432.CCR-08-0872.

108. Sparano J, O'Neill A, Alpaugh K et al. Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. *JAMA Oncol* 2018; 4(12): 1700–1706. doi: 10.1001/jamaoncol.2018.2574.
109. Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. *Nat Rev Cancer* 2009; 9(4): 274–284. doi: 10.1038/nrc2622.
110. Stoecklein NH, Fischer JC, Niederacher D et al. Challenges for CTC-based liquid biopsies: low CTC frequency and diagnostic leukapheresis as a potential solution. *Expert Rev Mol Diagn* 2016; 16(2): 147–164. doi: 10.1586/14737159.2016.1123095.
111. Krebs MG, Metcalf RL, Carter L et al. Molecular analysis of circulating tumour cells—biology and biomarkers. *Nat Rev Clin Oncol* 2014; 11(3): 129–144. doi: 10.1038/nrclinonc.2013.253.
112. de Boer CJ, van Krieken JH, Janssen-van Rhijn CM et al. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. *J Pathol* 1999; 188(2): 201–206. doi: 10.1002/(SICI)1096-9896(199906)188:2<201::AID-PATH339>3.0.CO;2-8.
113. Went PT, Lugli A, Meier S et al. Frequent EpCam protein expression in human carcinomas. *Hum Pathol* 2004; 35(1): 122–128. doi: 10.1016/j.humpath.2003.08.026.
114. Yu JJ, Xiao W, Dong SL et al. Effect of surgical liver resection on circulating tumor cells in patients with hepatocellular carcinoma. *BMC Cancer* 2018; 18(1): 835. doi: 10.1186/s12885-018-4744-4.
115. Kelley RK, Magbanua MJ, Butler TM et al. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. *BMC Cancer* 2015; 15: 206. doi: 10.1186/s12885-015-1195-z.
116. Sun YF, Xu Y, Yang XR et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. *Hepatology* 2013; 57(4): 1458–1468. doi: 10.1002/hep.26151.
117. Wang Z, Luo L, Cheng Y et al. Correlation between postoperative early recurrence of hepatocellular carcinoma and mesenchymal circulating tumor cells in peripheral blood. *J Gastrointest Surg* 2018; 22(4): 633–639. doi: 10.1007/s11605-017-3619-3.
118. Qi LN, Xiang BD, Wu FX et al. Circulating tumor cells undergoing EMT provide a metric for diagnosis and prognosis of patients with hepatocellular carcinoma. *Cancer Res* 2018; 78(16): 4731–4744. doi: 10.1158/0008-5472.CAN-17-2459.
119. Nel I, Baba HA, Ertle J et al. Individual profiling of circulating tumor cell composition and therapeutic outcome in patients with hepatocellular carcinoma. *Transl Oncol* 2013; 6(4): 420–428. doi: 10.1593/tlo.13271.
120. Li J, Shi L, Zhang X et al. pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma. *Oncotarget* 2016; 7(3): 2646–2659. doi: 10.18632/oncotarget.6104.
121. Cai Y, Yu X, Hu S et al. A brief review on the mechanisms of miRNA regulation. *Genomics Proteomics Bioinformatics* 2009; 7(4): 147–154. doi: 10.1016/S1672-0229(08)60044-3.
122. Valadi H, Ekström K, Bossios A et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol* 2007; 9(6): 654–659. doi: 10.1038/ncb1596.
123. Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. *Nat Rev Cancer* 2011; 11(12): 849–864. doi: 10.1038/nrc3166.
124. Vlassov AV, Magdaleno S, Setterquist R et al. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. *Biochim Biophys Acta* 2012; 1820(7): 940–948. doi: 10.1016/j.bbagen.2012.03.017.

125. Thakur BK, Zhang H, Becker A et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. *Cell Res* 2014; 24(6): 766–769. doi: 10.1038/cr.2014.44.
126. Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. *J Hematol Oncol* 2018; 11(1): 125. doi: 10.1186/s13045-018-0669-2.
127. Best MG, Sol N, Kooi I et al. RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. *Cancer Cell* 2015; 28(5): 666–676. doi: 10.1016/j.ccell.2015.09.018.
128. Ye Q, Ling S, Zheng S et al. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. *Mol Cancer* 2019; 18(1): 114. doi: 10.1186/s12943-019-1043-x.
129. U.S. National Library of Medicine. [online]. Available from: <https://www.clinicaltrials.gov/>.